Vertex Pharmaceuticals Incorporated (VRTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
78.71-0.02 (-0.03%)
At close: 4:00 PM EDT

84.90 6.19 (7.86%)
Pre-Market: 7:22 AM EDT

People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close78.73
Bid82.50 x 100
Ask84.00 x 500
Day's Range77.43 - 79.75
52wk Range75.90 - 134.71
1y Target EstN/A
Market Cap19.5B
P/E Ratio (ttm)-69.41
Avg Vol (3m)1,423,026
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • American City Business Journals39 minutes ago

    ​Vertex boosts market cap on plan for cystic fibrosis 'triple combo'

    Vertex Pharmaceuticals announced a plan late Tuesday to begin trials before the end of the year of the third in its so-called “triple combo” of pills designed to treat as much as 90 percent of the 75,000 patients worldwide who suffer from cystic fibrosis. Vertex (VRTX) said it will begin mid-stage trials of two drugs known as VX-152 and VX-440 before next year, in 35 and 40 patients respectively, with results expected in the second half of 2017. The third drug in that the company calls its “triple combo” is Kalydeco, which earned FDA approval in 2012.

  • Thomson Reuters StreetEvents11 hours ago

    Edited Transcript of VRTX earnings conference call or presentation 25-Oct-16 8:30pm GMT

    Q3 2016 Vertex Pharmaceuticals Inc Earnings Call

  • Associated Press13 hours ago

    Vertex Pharma reports 3Q loss

    Vertex Pharmaceuticals Inc. on Tuesday reported a loss of $41.8 million in its third quarter. On a per-share basis, the Boston-based company said it had a loss of 17 cents. Earnings, adjusted for stock ...